{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3"},{"groupId":"OG001","value":"7.1"}]}],"title":"Grade 3 or higher decrease in Potassium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6"},{"groupId":"OG001","value":"35.7"}]}],"title":"Grade 3 or higher decrease in Calcium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 3 or higher decrease in Magnesium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2"},{"groupId":"OG001","value":"28.6"}]}],"title":"Grade 3 or higher decrease in Sodium"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4"},{"groupId":"OG001","value":"7.1"}]}],"title":"Grade 3 or higher decrease in Albumin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"7.1"}]}],"title":"Grade 3 or higher decrease in Glucose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9"},{"groupId":"OG001","value":"28.6"}]}],"title":"Grade 3 or higher decrease in Phosphate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG001","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"NUMBER","populationDescription":"Participants from the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Participants With Decrease in Post-brexucabtagene Autoleucel Infusion Chemistry Toxicity Values by Worst Toxicity Grade","type":"SECONDARY","unitOfMeasure":"percentage of participants"}